Gain of function mutations in Nav1.7 and Nav1.9 cause painful conditions, while loss of function mutations in Nav1.7 and specific mutations in Nav1.9 cause complete insensitivity to pain.
Abstract Chronic pain is a global problem affecting up to 20% of the world’s population and has a significant economic, social and personal cost to society. Sensory neurons of the dorsal root ganglia (DRG) detect noxious stimuli and transmit this sensory information to regions of the central nervous system (CNS) where activity is perceived as pain. DRG neurons express multiple voltage-gated sodium channels that underlie their excitability. Research over the last 20 years has provided valuable insights into the critical roles that two channels, Na V 1.7 and Na V 1.9, play in pain signalling in man. Gain of function mutations in Na V 1.7 cause painful conditions while loss of function mutations cause complete insensitivity to pain. Only gain of function mutations have been reported for Na V 1.9. However, while most Na V 1.9 mutations lead to painful conditions, a few are reported to cause insensitivity to pain. The critical roles these channels play in pain along with their low expression in the CNS and heart muscle suggest they are valid targets for novel analgesic drugs.
Baker et al. (Mon,) conducted a review in Painful and painless channelopathies (SCN9A and SCN11A mutations). SCN9A (Nav1.7) and SCN11A (Nav1.9) mutations was evaluated. Gain of function mutations in Nav1.7 and Nav1.9 cause painful conditions, while loss of function mutations in Nav1.7 and specific mutations in Nav1.9 cause complete insensitivity to pain.